Wednesday, May 27, 2020 3:53:57 PM
Well, unfortunately I listened to the meeting, and came away with four specific issues:
1. They read some questions that shareholders had asked, which were not at all antagonistic, and simply stated that they had been addressed by HDC in prior communications. Their 'generic' response simply gave the appearance that they went into the meeting deliberately not intending to answer anything, and in my view the approach was less-than shareholder friendly. Not even a little attempt to try answering at a high level;
2. They engaged a research institution, but haven't signed anything. In other words, nothing realistically in the pipeline at all;
3. They haven't executed on any agreements that might help with financing infringement action;
4. The only issue that they addressed with some degree of emphasis was to poke Quirk for his legal actions. Yet, since the world already knows about this, I'm not so sure that was too smart, since they've likely antagonized him even further.
Long and short of it is that there is nothing in the near term that we can expect regarding partnerships or infringement protection, unless something truly comes out of left field. More likely, the only thing we can expect is more drama with Quirk.
In my view, this meeting did more harm than good. The tone of it was anything but shareholder friendly, and the board seemingly wants us to be proud of them for getting the financials up to date. Nothing else has been accomplished, and this was just 'checking the boxes' for the team. Meanwhile, the stock was at a penny yesterday.
[END]
I wonder??? is it possible that some or all of HDC management may have received enough negative votes to push them out?
I must laugh that HDC is proud that they did their 10k...that is like me showing up for work and clocking in...that my employer should be happy....UFReal!
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM